Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes*, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Melissa R. Spears, Alastair W.S. Ritchie, Christopher C. Parker, J. Martin Russell, Gerhardt Attard, Johann De Bono, William Cross, Rob J. Jones, George Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, Sharon Beesley, Alison J. BirtleSusannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D. Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O'Sullivan, Omi Parikh, Clive Peedell, Andrew Protheroe, Angus J. Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh K.B. Parmar

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1039 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences